TScan Therapeutics, Inc.
TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell therapies for cancer, with research into treatments for T cell-driven autoimmune disorders. Its lead candidate, TSC-101, is designed to target residual disease in patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Other blood cancer candidates, TSC-102-A01 and TSC-102-A03, target CD45. TScan is also developing multiplex TCR-T therapies for solid tumors, although it has paused further enrollment in its PLEXI-T Phase 1 trial and is focusing preclinical work on in vivo engineering. TScan operates an internal good manufacturing practices facility for clinical supply and has engaged a contract development and manufacturing organization to expand capacity. It has a research collaboration with Amgen to identify T cell antigens in Crohn’s disease; Amgen retains global development and commercial rights to resulting therapeutics. TScan is headquartered in Waltham, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TCRX in the last 7 days.
No SEC Form 4 filings for $TCRX in the last 30 days.
See all $TCRX insider activity →TScan Therapeutics announced board changes: Garry Nicholson and Gabriela Gruia resigned, while R. Keith Woods and Stephen Biggar joined the Nominating and Corporate Governance Committee. Woods became its chairperson. The changes were effective October 13, 2026, and were not due to disagreements with the company.
TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Garry Nicholson and Gabriela Gruia, M.D. On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.
TScan Therapeutics (TCRX) has finalized separation agreements with its outgoing CFO, Jason Amello, and Chief Medical Officer, Chrystal Louis. Both will continue receiving their base salary and benefits until their separation date, with Amello eligible for an $85,000 milestone bonus and Louis for $125,000, contingent on company milestones.
Recent TCRX coverage spans corporate actions, financial news and regulation.
Board composition change may affect governance perception and future strategic direction.
Board turnover may cause short‑term uncertainty but no immediate operational impact.
Executive departures may cause short‑term uncertainty and modest pressure on the stock.
Executive exits may raise uncertainty about leadership continuity and execution of the 2025 Retention Program.
TScan Therapeutics granted retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski. The awards include cash and equity, with vesting tied to milestones and continued service. MacBeath received $822,000 in cash and 2.4 million RSUs, while Zdraveski received $416,000 and 1.05 million RSUs.
AlphAI scores every news story that mentions TCRX with an AI model for sentiment and relevance, and aggregates insider trades from TScan Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TScan Therapeutics announced board changes: Garry Nicholson and Gabriela Gruia resigned, while R. Keith Woods and Stephen Biggar joined the Nominating and Corporate Governance Committee. Woods became its chairperson. The changes were effective October 13, 2026, and were not due to disagreements with the company.
TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Garry Nicholson and Gabriela Gruia, M.D. On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.
TScan Therapeutics (TCRX) has finalized separation agreements with its outgoing CFO, Jason Amello, and Chief Medical Officer, Chrystal Louis. Both will continue receiving their base salary and benefits until their separation date, with Amello eligible for an $85,000 milestone bonus and Louis for $125,000, contingent on company milestones.
TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Company’s Current Report on Form 8-K filed September 2, 2026, in connection with a strategic
TScan Therapeutics granted retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski. The awards include cash and equity, with vesting tied to milestones and continued service. MacBeath received $822,000 in cash and 2.4 million RSUs, while Zdraveski received $416,000 and 1.05 million RSUs.
TScan Therapeutics (TCRX) approved a retention program on September 8, 2026, granting CEO Gavin MacBeath $822,000 in cash and 2.4M RSUs, and Chief Legal Officer Zoran Zdraveski $416,000 and 1.05M RSUs. Payments are tied to clinical and financing milestones, with partial cash payouts scheduled for November 2026 and February 2027.
TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the Compensation Committee of the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “
Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.
TScan Therapeutics (TCRX) announced a reorganization to focus on its in vivo solid tumor pipeline, reducing its workforce by 75%. The company paused enrollment in its Phase 3 ALLOHA-2 study due to funding constraints. TScan plans to release preclinical data in Q1 2027 and initiate Phase 1 development in Q4 2027. Shares were down 36.95% to 42 cents at the time of publication.
Wedbush downgraded Tscan Therapeutics (TCRX) to Neutral, lowering its price target to $1.00 from $5.00 due to a strategic shift. The company paused its Phase 3 ALLOHA-2 study and refocused on preclinical programs, reducing staff by 75%. Despite cash burn concerns, InvestingPro suggests the stock may be undervalued. H.C. Wainwright reiterated a Buy rating with a $7.00 target, citing positive trial data.
